← Back

Module 7 · Evolution & Emergence

Viral Evolution & Emerging Diseases

Viruses evolve fast. Three pandemics in the 21st century alone (2003 SARS, 2009 H1N1, 2019 SARS-CoV-2) have made viral emergence a central problem of public health and a vibrant area of evolutionary biology. This module covers the population-genetic foundations and the spillover–emergence–adaptation pipeline.

1. Mutation, Mutation Rate, and Mutational Load

Per-base, per-replication mutation rates:

  • Eukaryotic genome: ~10−9/base/generation.
  • DNA viruses: 10−7 (with proofreading polymerase).
  • RNA viruses: 10−3 to 10−5 (no proofreading).
  • SARS-CoV-2: ~10−6/base — remarkably low for an RNA virus, due to the nsp14 ExoN proofreading exonuclease.

For a 10 kb (+)RNA virus genome at 10−4/base, every progeny carries ~1 mutation. In a single infected cell making 104 particles, the entire single-mutation neighbourhood is sampled in one cycle. Selection has vast genetic variation to act on; immune escape is fast.

2. Recombination & Reassortment

Beyond point mutation:

  • Recombination — template-switching by RdRp during co-infection produces chimeric genomes. Coronaviruses, picornaviruses, and HIV recombine readily.
  • Reassortment — segmented viruses (influenza, rotavirus) swap entire segments when two strains co-infect a host. The 1957, 1968, and 2009 influenza pandemics all involved reassortment with avian or swine viruses.
  • Horizontal gene transfer — large dsDNA viruses (poxviruses, herpesviruses, giant viruses) acquire host genes (e.g., poxvirus immunomodulators that mimic host cytokine receptors).

3. Zoonotic Spillover

~75% of emerging human infectious diseases are zoonoses. Bats are over-represented donors (rabies, Hendra, Nipah, MERS, SARS, SARS-CoV-2, Ebola filoviruses). Why bats? Possibly because (i) they are the second-most diverse mammal order with ~1400 species and large social colonies, (ii) they tolerate chronic viral infection due to dampened inflammasome and high baseline interferon, and (iii) their flight may select for unusual antiviral physiology.

The spillover → emergence pipeline has stages: spillover from reservoir → limited human transmission (R < 1; sporadic clusters) → sustained human transmission (R > 1; epidemic) → establishment (endemic). Most spillovers (Hendra, Nipah, MERS) stop at stage 2; SARS-CoV-2 reached stage 4. The intermediate-host concept — palm civets for SARS, dromedary camels for MERS, possibly raccoon dogs or other animals for SARS-CoV-2 — explains how a bat virus reaches human ACE2 affinity by stepping through an intermediate that has both bat-like and human-like receptors.

4. The Recent Pandemics

  • 1918 H1N1 — ~50–100 million deaths. Avian-origin, possibly via swine. Genome reconstructed from formalin-fixed tissue and an Alaskan permafrost burial (Taubenberger 2005).
  • HIV — SIVcpz from chimpanzees, multiple cross-species transmissions in early-20th-century Central Africa; ~40 million deaths cumulative.
  • 2003 SARS — bats → civets → humans; ~8000 cases, contained by aggressive contact tracing.
  • 2009 H1N1 — quadruple reassortant from North American swine; mild but globally spread.
  • 2014–16 Ebola — West African outbreak, first sustained urban transmission of Ebola.
  • 2015–16 Zika — mosquito-borne flavivirus; congenital microcephaly recognised when the virus reached the Americas.
  • 2019– SARS-CoV-2 — ~7 million confirmed deaths (likely understated), profound social and economic disruption, but also the demonstration that mRNA vaccines can be designed in days.

5. Genomic Surveillance & Phylodynamics

Sequencing-based surveillance (GISAID for influenza/SARS-CoV-2; nextstrain.org for real-time phylogenetic visualisation) has transformed outbreak response. Variant naming (Alpha, Delta, Omicron) and lineage-tracking (Pango: B.1.1.7, BA.5, etc.) provide a shared global language. Phylodynamic methods couple sequence trees to epidemic models, recovering R, generation interval, and introduction events from genomes alone (Volz, Stadler, Bedford). Wastewater sequencing extends this to populations independent of clinical testing.

6. Pandemic Preparedness

The pandemic-preparedness agenda is now scientifically clear: maintain global surveillance for spillover; develop vaccine prototypes against the ~25 priority viral families before the next pandemic begins; pre-clinically test broad-spectrum antivirals; build manufacturing reserve capacity (LNP supply chains, cell-culture facilities); align international agreements on data sharing and surge production. CEPI’s 100-Days Mission — from identification of a new pandemic threat to a deployable vaccine in 100 days — is plausible but requires sustained investment between pandemics. The graduate virologist of 2030 will be working in this space. The course is over; the work is not.

← Module 6Course Overview →